Tocilizumab in Large Vessel Vasculitis – Different Routes of Administration

Schmalzing, Marc; Gadeholt, Ottar; Gernert, Michael; Tony, Hans‐Peter; Schwaneck, Eva Christina

doi:10.2174/1874312901812010152

Cited by 3 publications

(1 citation statement)

References 20 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two patients died, although cause of death was not attributable to the use of Tocilizumab. Three relapses occurred but remission was regained by switching the usual subcutaneous administration of Tocilizumab to intravenous [30].…”

Section: Tocilizumabmentioning

confidence: 99%

Treatment of Vasculitis: Beyond the Basics

Ghauri¹,

Mukarram²

2020

Vascular Biology - Selection of Mechanisms and Clinical Applications

View full text Add to dashboard Cite

Vasculitis is the inflammation of blood vessels in the human body. It causes changes and remodeling in the walls of the vessels that include thickening, narrowing and scarring. As a result, the blood flow to the organs and tissues gets restricted leading to organ damage. The cause of primary vasculitis is not known; however, most cases are thought to be autoimmune. In the present era, it is getting difficult to treat vasculitis with conventional therapies, which includes cyclophosphamide, methotrexate, azathioprine and mycophenolate mofetil, with increasing rates of relapses. Since ever, corticosteroids and cytotoxic agents or immunosuppressants have been the mainstay for treating systemic vasculitis. However, the introduction of newer biological agents have bring about a revolution in the treatment of relapses and in cases where there is failure to induce and sustain remission.

show abstract

Section: Tocilizumabmentioning

confidence: 99%

Treatment of Vasculitis: Beyond the Basics

Ghauri¹,

Mukarram²

2020

Vascular Biology - Selection of Mechanisms and Clinical Applications

View full text Add to dashboard Cite

show abstract

Prednisolone/tocilizumab

2018

Reactions Weekly

View full text Add to dashboard Cite

Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study

et al. 2023

View full text Add to dashboard Cite

ObjectiveTo evaluate the safety and efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) in a large North American cohort.MethodsPatients with GCA treated with TCZ between January 1, 2010, and May 15, 2020, were retrospectively identified. Kaplan-Meier methods were used to estimate time to TCZ discontinuation and time to first relapse after TCZ discontinuation. Poisson regression models were used to compare annualized relapse rates before, during, and after TCZ use. Age- and sex-adjusted risk factors associated with relapse on and off TCZ and development of adverse events of significant interest (AESIs) were examined using Cox models.ResultsOne hundred fourteen patients (60.5% female) were included with mean (SD) age 70.4 (8.2) years. Median duration from GCA diagnosis to TCZ start was 4.5 months. Median overall duration of TCZ treatment was 2.3 years. Relapse rate prior to TCZ start (0.84 relapses/person-year) was 3-fold reduced while on TCZ (0.28 relapses/person-year;P< 0.001) but increased to 0.64 relapses/person-year after TCZ discontinuation. Fifty-two patients stopped TCZ after a median of 16.8 months; 27 relapsed after discontinuation (median: 8.4 months; 58% relapsed within 12 months). Only 14.9% of patients stopped TCZ because of AESIs. Neither dose/route of TCZ, presence of large-vessel vasculitis, nor duration of TCZ therapy prior to discontinuation predicted relapse after TCZ stop.ConclusionTCZ is well tolerated in GCA, with low rates of discontinuation for AESIs. However, relapse occurred in > 50% despite median treatment > 12 months. Since the duration of TCZ prior to discontinuation did not significantly affect subsequent risk of GCA recurrence, further research is needed to determine the optimal duration of therapy.

show abstract

Tocilizumab in Large Vessel Vasculitis – Different Routes of Administration

Cited by 3 publications

References 20 publications

Treatment of Vasculitis: Beyond the Basics

Treatment of Vasculitis: Beyond the Basics

Prednisolone/tocilizumab

Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study

Contact Info

Product

Resources

About